EXACT SCIENCES CORP (EXAS)
US30063P1057 - Common Stock
Notable Tuesday Option Activity: X, SPHR, EXAS
Exact Sciences Names Aaron Bloomer as New Chief Financial Officer
Exact Sciences Announces Debt Exchange Transaction and Private Placement of Convertible Senior Notes
Exact Sciences Schedules First Quarter 2024 Earnings Call
The 3 Best Cathie Wood Stocks to Buy in April 2024
Cathie Wood doesn't have a great overall record, but she sometimes makes great picks. Here are the three best Cathie Wood stocks to buy now.
The 3 Best Cathie Wood Stocks to Buy in April 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Full disclosure, I’m not a tremendous fan of Cathie Wood. Generally, I th...
1 Beaten-Down Cathie Wood Stock to Buy and Hold
This company is innovating where it matters most, which could prove highly lucrative down the road.
Exact Sciences to Provide Mayo Clinic Patients with Individualized Cancer Tumor Information to Inform Treatment
Exact Sciences, A Cathie Wood Stock, Surges As Rival Colon Cancer Test Pales
The companies are working to detect colon cancer and precancerous markers in blood and/or stool.
EXACT Sciences Breaks Above 200-Day Moving Average - Bullish for EXAS
Noteworthy Thursday Option Activity: ITCI, FSLR, EXAS
Exact Sciences Advances Development of Non-Endoscopic Oncoguard® Esophagus Test to Screen for Esophageal Cancer and Pre-Cancer
3 Biotech Stocks to Buy on the Dip: March 2024
Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three.
Exact Sciences Named 2024 Gallup Exceptional Workplace Award Winner
3 Growth Stocks to Buy at 52-Week Lows in March
Wager on these growth stocks to buy at 52-week lows offering robust investment potential ahead for savvy investors.
Interesting EXAS Put And Call Options For June 21st
Notable Tuesday Option Activity: JPM, EXAS, KNTK
First Week of EXAS May 17th Options Trading
The New England Journal of Medicine Publishes Cologuard Plus™ Test Results from Pivotal BLUE-C Study
Cathie Wood Darling Exact Sciences Could Pop After Its Next-Gen Product Outperforms
Exact Sciences is hoping to launch an next-generation version of Cologuard in 2025.
2 Beaten-Down Cathie Wood Stocks With Massive Potential
They won't lag the market forever.
Notable Friday Option Activity: ABNB, EXAS, ASAN
Exact Sciences and Basketball Great Jamal Mashburn Encourage Americans 45+ to Have a Game Plan Against Colon Cancer
The Top 3 Healthcare Stocks to Buy on Weakness in 2024
Many healthcare stocks have extremely bright outlooks and very low valuations. Here are three top healthcare stocks to buy.
7 Stable Stocks to Buy for 100% Returns by 2025
If you're looking for stability and the opportunity to double your returns by the time 2025 rolls around, check out these stable stocks.
Hidden Gems: 3 Market Underdogs to Buy at Rock-Bottom Prices
While these underdogs stocks might not be on everyone’s radar, they may offer surprisingly robust upside potential.
Exact Sciences to Participate in March Investor Conference
Exact Sciences (EXAS) Q4 2023 Earnings Call Transcript
EXAS earnings call for the period ending December 31, 2023.
Exact Sciences GAAP EPS of -$0.27 beats by $0.21, revenue of $647M beats by $7.3M (NASDAQ:EXAS)
Exact Sciences beats expectations with Q4 earnings. Revenue of $647M, a 17% increase.